Patent · US Active

Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK)

US12415803B2 · kind B2 · utility

0Cited by
2References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 26, 2019
Grant dateSep 16, 2025
Priority date
Expiry dateSep 12, 2042

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.